Jingfeng Pharmaceutical(000908)2024-11-22 09:11Group 1: Bond Issuance Overview - Morgan Stanley Securities acts as the trustee for Hunan Jingfeng Pharmaceutical Co., Ltd.'s 2016 public bond issuance (first phase) [5] - The bond code is 112468, and the bond abbreviation is 16 Jingfeng 01 [1] Group 2: Stock Trading Suspension and Resumption - Jingfeng Pharmaceutical's stock (*ST Jingfeng, code: 000908) experienced a price increase of 752.78% from July 3, 2024, to November 15, 2024, leading to significant investor concern [5] - The company applied for a trading suspension starting November 18, 2024, to investigate stock price fluctuations [5][6] - The stock is set to resume trading on November 21, 2024, after the completion of the self-examination [6] Group 3: Company Operations and Market Conditions - The company and its subsidiaries are operating normally, with no significant changes in the main business or market environment [7] - No media reports or market rumors have been found that could impact the stock price [7] - A total of 1,044,800 shares were purchased by Mr. Ye Xiangwu between June 25 and September 24, 2024, representing 0.12% of the total share capital, with a total investment of 2,002,940.00 yuan [7] Group 4: Disclosure Compliance - The board confirms that there are no undisclosed matters that should be reported according to the Shenzhen Stock Exchange's listing rules [8] - No corrections or supplements are needed for previously disclosed information [8]